Integration of ADx NeuroSciences within Fujirebio unleashes a world of new possibilities

Mar 31, 2026

Fujirebio Europe N.V. will formally and fully integrate ADx NeuroSciences N.V. into its organization on April 1, 2026. This completes a process that began with the acquisition of ADx NeuroSciences in June 2022 and strengthens a partnership that benefits both companies, as well as their partners, collaborators, and customers.

ADx NeuroSciences, widely recognized for its early-stage neurodegenerative fluid biomarker development, will cease to operate as a separate legal entity from April 2026. Its teams and capabilities will continue as an integral part of Fujirebio’s activities in the field of neurological diagnostics. The former ADx NeuroSciences team will continue contributing to Fujirebio’s biomarker pipeline. The integration significantly expands the combined organization’s capability across every stage of the biomarker development pathway, from early discovery through to routine clinical application.

A stronger end-to-end model for neurological diagnostics

The strategic value of the integration lies in how the two organizations complement each other’s competencies. Fujirebio is renowned for its strength, particularly in taking biomarkers through clinical evidence generation, regulatory approval, and global commercialization at scale. ADx NeuroSciences’ expertise is focused on the earlier stages – i.e. identifying and developing novel biomarker candidates across neurodegenerative disease fields (e.g. AD, PD, MND), exploring their clinical potential through research programs and consortia, and and building close relationships with academic institutions and pharmaceutical partners that can feed new opportunities into the pipeline.

Fujirebio’s Neuro Expert Toolbox (NExT) provides a good framework for understanding how these capabilities fit together. The NExT model organizes biomarker development into four sequential chambers – Concept, Explorer, Incubation, and Routine – covering the entire trajectory from fundamental biomarker identification to clinical implementation.

Within this model, the former ADx NeuroSciences team strengthens Fujirebio’s ability to generate and mature new biomarker programs, while Fujirebio’s broader organization provides the development, regulatory and commercial infrastructure needed to bring the most promising biomarkers closer to clinical application. In practical terms, this means a stronger capacity to move innovative biomarker ideas forward in a more structured and continuous way.

A prime example of how the NExT funnel works in practice, is the company’s new DDC (DOPA decarboxylase) assay. It has progressed from early exploratory work towards an Xplorer assay and is now moving towards becoming a market-ready RUO assay.

Subscribe to Fujirebio insight updates

Get all the latest insight articles from Fujirebio the moment they are published.

First name

E-mail address

CAPTCHA

A wider influence: R&D, clinical evidence, and the CDMO model

ADx NeuroSciences’s contribution to the combined organization extends well beyond research and development. Fujirebio operates through what it describes as a “virtuous circle” of innovation (i.e. developing biomarkers), proof (i.e. establishing clinical value employing its proprietary Lumipulse® technology), and global expansion through partnerships, including collaborations with other technology providers in the field.

Specifically, at the level of Fujirebio’s CDMO (Contract Development and Manufacturing Organization) business, through which the company supplies reagents to partner companies worldwide rather than restricting its innovations to its own platform. In this context, ADx NeuroSciences’s proprietary antibody library of novel biomarkers significantly expands the portfolio available to partners.

Fujirebio’s open business model – the principle of sharing innovation across platforms and with partners throughout the industry rather than locking content to a single system – was a key strategic consideration behind the integration.

Continuity of team and approach

For existing ADx NeuroSciences partners and customers, the changes on April 1 are primarily administrative: contact details and banking information will update to reflect the Fujirebio entity, and the ADx NeuroSciences name and logo will no longer appear on correspondence or materials. The ADx NeuroSciences website will redirect to Fujirebio, with a dedicated page at www.fujirebio.com/adx providing transition information and links to relevant resources.

The ADxPLORER® product line – a range of research-use-only assays for novel biomarker evaluation in dedicated projects, running on the LUMIPULSE® G 1200 platform – will continue under that name.

Continuity is therefore a central part of the story. The people, the knowledge base, the partner network and the underlying scientific approach will remain, now supported by the broader scale and infrastructure of Fujirebio.

The Fujirebio Neuro Center of Excellence: an open, continuous model

The institutional home for the combined team’s collaborative approach is the Fujirebio Neuro Center of Excellence. It embodies a model of engagement that distinguishes Fujirebio in the field: continuous interaction with key opinion leaders, pharmaceutical partners, academic institutions, and memory clinics.

This model also reflects a deliberate openness to scientific risk – a willingness to invest in novelty by exploring biomarker candidates whose commercial potential is uncertain, but whose scientific interest is real. It is an approach that more commercially constrained organizations find difficult to sustain seen the economical uncertainty. For Fujirebio, an R&D driven organization, it is an important differentiator and an expression of the open business model with a focus on innovation that the integration further strengthens.

From Alzheimer’s disease to the broader neurological spectrum

The integration comes at a time of considerable momentum in neurological diagnostics. Fujirebio’s FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test to identify amyloid pathology associated with Alzheimer’s disease and, more recently, the CE-IVDR certification of the Lumipulse® G NfL Blood assay as a marker of neuro-axonal damage in various neurological conditions are two examples of the kind of progress that can emerge when scientific innovation is translated into clinically meaningful applications.

The ambition now is to extend the same model more broadly across the neurological spectrum. Parkinson’s disease, multiple sclerosis, motor neuron diseases, and psychiatric disorders all represent areas of significant unmet diagnostic needs, where blood-based biomarkers could be transformative. Before the acquisition, ADx NeuroSciences had ongoing developments in these areas through its academic and pharma partnerships. Now, with the infrastructure of Fujirebio, those programs have the full resources to upscale the biomarkers and make faster decisions depending on the clinical demand.

The goal, as the organization’s leadership describes it, is to become the definitive content partner for neurological diagnostics across the full disease spectrum, from early discovery through to routine clinical application, and across every major platform available in the field.

In summary

The full integration of ADx NeuroSciences into Fujirebio is more than a legal or organizational change. It creates a more connected and capable model for neuro biomarker innovation.

ADx NeuroSciences’ expertise in early discovery and assay development remains in place. Fujirebio’s scale in clinical validation, regulatory execution and commercialization adds the downstream capabilities needed to bring more of that innovation forward. For partners and customers, the result is continuity. For the field, it is a stronger platform for translating novel neurological biomarkers into real-world impact.

For enquiries relating to the integration, please contact the team at fnce@fujirebio.com or visit www.fujirebio.com/adx.

Jul 23, 2025

A stronger end-to-end model for neurological diagnostics

Share this article

Subscribe to Fujirebio insight updates

A wider influence: R&D, clinical evidence, and the CDMO model

Continuity of team and approach

The Fujirebio Neuro Center of Excellence: an open, continuous model

From Alzheimer’s disease to the broader neurological spectrum

In summary

Related articles

Related products

DiaPlexQ™ ApoE Genotyping Kit

INNOTEST® hTAU Ag

INNOTEST® hTAU Ag

INNOTEST® PHOSPHO-TAU (181P)

INNOTEST® PHOSPHO-TAU(181P)

INNOTEST® β-AMYLOID(1-40)

INNOTEST® β-AMYLOID(1-40)

INNOTEST® β-AMYLOID(1-42)

INNOTEST® β-AMYLOID(1-42)

Lumipulse® ApoE4 Controls

Lumipulse® G ApoE4

Lumipulse® G GFAP

Lumipulse® G NfL Blood

Lumipulse® G NfL Blood

Lumipulse® G NfL Blood Controls

Lumipulse® G NfL CSF

Lumipulse® G Pan-ApoE

Lumipulse® G pTau 181

Lumipulse® G pTau 181 Plasma

Lumipulse® G pTau 217 CSF

Lumipulse® G pTau 217 Plasma

Lumipulse® G sTREM2

Lumipulse® G Total Tau

Lumipulse® G β-Amyloid 1-40

Lumipulse® G β-Amyloid 1-40 Plasma

Lumipulse® G β-Amyloid 1-42

Lumipulse® G β-Amyloid 1-42 Plasma

Lumipulse® GFAP Controls

Lumipulse® NfL Blood Controls

Lumipulse® NfL CSF Controls

Lumipulse® pTau 181 Plasma Controls

Lumipulse® pTau 217 Plasma Controls

Lumipulse® sTREM2 Controls

Lumipulse® β-Amyloid Plasma Controls

PHF-Tau Alzheimer biomarkers

Tau Alzheimer biomarkers

Review past webinars

Mapping Synaptic Loss: Where β‑synuclein Fits in the Biomarker Landscape

Unlocking the biology of dementia with Lewy bodies: Biomarker insights from DDC to synapses

Preparing for the future of plasma based Alzheimers disease diagnostics

DiaPlexQ^™ ApoE Genotyping Kit

INNOTEST^® hTAU Ag

INNOTEST^® hTAU Ag

INNOTEST^® PHOSPHO-TAU (181P)

INNOTEST^® PHOSPHO-TAU(181P)

INNOTEST^® β-AMYLOID(1-40)

INNOTEST^® β-AMYLOID(1-40)

INNOTEST^® β-AMYLOID(1-42)

INNOTEST^® β-AMYLOID(1-42)

Lumipulse^® ApoE4 Controls

Lumipulse^® G ApoE4

Lumipulse^® G GFAP

Lumipulse^® G NfL Blood

Lumipulse^® G NfL Blood

Lumipulse^® G NfL Blood Controls

Lumipulse^® G NfL CSF

Lumipulse^® G Pan-ApoE

Lumipulse^® G pTau 181

Lumipulse^® G pTau 181 Plasma

Lumipulse^® G pTau 217 CSF

Lumipulse^® G pTau 217 Plasma

Lumipulse^® G sTREM2

Lumipulse^® G Total Tau

Lumipulse^® G β-Amyloid 1-40

Lumipulse^® G β-Amyloid 1-40 Plasma

Lumipulse^® G β-Amyloid 1-42

Lumipulse^® G β-Amyloid 1-42 Plasma

Lumipulse^® GFAP Controls

Lumipulse^® NfL Blood Controls

Lumipulse^® NfL CSF Controls

Lumipulse^® pTau 181 Plasma Controls

Lumipulse^® pTau 217 Plasma Controls

Lumipulse^® sTREM2 Controls

Lumipulse^® β-Amyloid Plasma Controls